📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-18 13:17
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
36 announcements match the current filters (relevance ≥ 5).
India Ratings Upgrades Onesource to 'IND A'/Positive on Rs 1,553.76 Cr Bank Facilities
India Ratings & Research (Ind-Ra) has upgraded Onesource Specialty Pharma's long-term bank loan rating to 'IND A' from 'IND A-' with a Positive outlook, while affirming the short-term rating at 'IND A1'. The rating covers existing facilities of INR 11,250.51 million (~Rs 1,125.05 Cr) alongside newly assigned limits of INR 4,287.08 million (~Rs 428.71 Cr), totaling Rs 1,553.76 Cr. The agency attributed the upgrade to the commercialisation of its drug-device combination (DDC) platform and expanding commercial GLP-1 supplies, signaling a transition toward a stable, commercial supply-led CDMO model.
Confidence: HIGH
What changedIndia Ratings upgraded Onesource's long-term credit rating to 'IND A'/Positive from 'IND A-' across Rs 1,553.76 Cr of bank facilities.
Why it mattersThe upgrade validates the commercialisation of high-margin GLP-1 and drug-device platforms, which strengthens revenue visibility and lowers financing costs.
Existing rated facilities: INR 11,250.51 millionAdditional rated limits: INR 4,287.08 millionTotal rated debt vs existing debt: ~103%Upgraded rating: IND A / Positive
📅 Short termProvides positive sentiment as credit rating agencies confirm the transition from R&D development to revenue-generating commercial launches.
📈 Long termStructural improvement in debt profile and validation of the CDMO model combining biologics, sterile injectables, and GLP-1 manufacturing.
⚠ Risk flags
- Regulatory inspection risk across 4 USFDA-approved facilities
- Execution timeline on commercial GLP-1 deliveries
Key Highlights
Long-term bank loan rating upgraded to 'IND A' with Positive Outlook from 'IND A-'; short-term rating affirmed at 'IND A1'
Total rated bank facilities expand to INR 15,537.59 million (~Rs 1,553.76 Cr), including INR 4,287.08 million of newly assigned limits
Total rated facilities cover ~103% of the company's existing debt load of Rs 1,504 Cr
Upgrade driven by ramp-up in commercial GLP-1 supplies and transition to multi-year commercial supply agreements (CSAs)
👀 What to Watch
Track the quarterly ramp-up in revenue from GLP-1 commercial supply agreements and watch for borrowing cost reductions in upcoming debt servicing metrics.
Q1 FY27: 37% Revenue Growth to ₹449 Cr; OneSource Targets $400M Revenue by FY28
OneSource Specialty Pharma reported a strong Q1 FY27 with revenue of ₹449 cr, up 37% YoY, and EBITDA of ₹123.3 cr, up 39% YoY. Growth was primarily driven by the commercial launch of semaglutide (GLP-1) in Canada and India, where the company now manufactures over 40% of the generic pens market. Management reiterated its FY28 guidance of $400 million in organic revenue with 40% EBITDA margins, supported by a $100 million capex plan. A second cartridge line is set for commercialization this quarter, which will double sterile production capacity.
Confidence: HIGH
What changedThe company has transitioned into a high-growth phase driven by the GLP-1 market and is doubling its sterile production capacity this quarter.
Why it mattersThe shift toward high-margin CDMO services in Biologics and GLP-1 products is critical for turning around the company's TTM net loss and achieving the targeted 40% EBITDA margins.
Q1 FY27 Revenue: ₹449 crYoY Revenue Growth: 37%Q1 FY27 EBITDA: ₹123.3 crFY28 Revenue Target: $400 millionTotal Capex Plan: $100 millionIndia Generic Pen Market Share: >40%
📅 Short termThe stock may see positive momentum following the strong EBITDA growth and the imminent doubling of sterile production capacity in the current quarter.
📈 Long termThe company is positioning itself as a major global CDMO for GLP-1 and Biologics; achieving the $400M revenue target would represent a ~136% increase over FY26 levels.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High debt of ₹1,504 cr relative to TTM revenue
- Geopolitical risks impacting freight costs and timelines
- Execution risk on large-scale capacity expansions
Key Highlights
Revenue grew 37% YoY to ₹449 cr in Q1 FY27, driven by GLP-1 commercialization and new MSA contracts.
EBITDA increased 39% YoY to ₹123.3 cr, representing a 34% sequential growth over the previous quarter.
The company manufactures >40% of the generic GLP-1 pens market currently sold in India.
The RFP (Request for Proposal) funnel has expanded to 4x its size compared to one year ago.
Management reiterated FY28 targets of $400 million revenue and 40% EBITDA margins.
👀 What to Watch
Monitor the successful ramp-up of the second cartridge line in Q2 FY27 and the execution of the $100 million capex plan to see if the company stays on track for its ambitious FY28 targets.
Management Change: Global Head of Injectables Resigns; New HR Head Designated SMP
OneSource Specialty Pharma has announced the resignation of Ravi Kumar, Global Head of Injectables and Head of Corporate Strategy, effective July 24, 2026. This exit is significant as the company is currently restructuring to combine the CDMO businesses of Strides, Steriscience, and OneSource, with injectables being a core growth pillar. Simultaneously, Preeti Kalra, who has over 25 years of experience in the Biopharma and IT sectors, has been designated as a Senior Management Personnel (SMP) in her capacity as Head of Human Resources. The company reported a TTM revenue of ₹1,422 Cr and is currently loss-making at the PAT level (₹-49 Cr).
Confidence: HIGH
What changedThe Global Head of Injectables and Corporate Strategy has resigned, and the Head of Human Resources has been elevated to the Senior Management Personnel category.
Why it mattersLosing a leader who oversees both a core business segment (Injectables) and Corporate Strategy during a major organizational restructuring could create temporary execution risks, although the appointment of an experienced HR leader aims to stabilize organizational transformation.
Installed Injectables Capacity: 40 million unitsDeliverable Injectables Capacity: 15 million to 20 million unitsTTM Revenue: ₹1,422 CrDebt Reduction (Softgel hive-off): ₹280 CrNew SMP Experience: 25+ years
📅 Short termThe market is likely to view this as a routine management transition, though the exit of the strategy head during a merger phase may invite some scrutiny in upcoming analyst calls.
📈 Long termThe long-term success depends on the successful integration of the three CDMO businesses and achieving the 12% expected growth rate through its 4 US FDA approved facilities.
⚠ Risk flags
- Execution risk due to exit of Strategy and Injectables head during restructuring
- High debt levels of ₹1,504 Cr relative to TTM revenue
Key Highlights
Ravi Kumar resigned as Global Head – Injectables and Head of Corporate Strategy effective July 24, 2026.
Preeti Kalra designated as SMP effective July 24, 2026, bringing 25+ years of leadership experience.
Company maintains 7 manufacturing facilities, with 4 being US FDA approved.
Current installed capacity for the Sterile Injectables business stands at 40 million units.
Restructuring involves combining CDMO businesses and a Softgel hive-off that reduced debt by ₹280 Cr.
👀 What to Watch
Investors should monitor the appointment of a successor for the Global Head of Injectables and Strategy role, as this position is critical for the execution of the integrated CDMO model. Watch for updates on the completion of the planned capacity expansion in CY 2026.
37% Revenue Growth in Q1FY27; OneSource Reports ₹449 Cr Revenue and 27.5% EBITDA Margin
OneSource Specialty Pharma reported a strong start to FY27 with revenue growing 37% YoY to ₹449 crore, driven by the commercial launch of semaglutide in Canada and India. EBITDA rose 39% YoY to ₹123.3 crore, with margins expanding significantly by 600 bps QoQ to 27.5% due to operating leverage. The company reaffirmed its ambitious FY28 guidance of $400 million in organic revenue (approx. ₹3,780 cr) and 40% EBITDA margins. Key operational progress includes the upcoming commercialization of a second cartridge line in Q2 and the addition of 6 new customers, bringing the total to over 80.
Confidence: HIGH
What changedThe company has successfully transitioned to profitability (Reported PAT of ₹25 cr vs a loss in the previous year) and is scaling its GLP-1 (semaglutide) portfolio across international markets.
Why it mattersThe results validate the company's integrated CDMO model and its ability to capture the high-growth GLP-1 market, moving it closer to its aggressive FY28 financial targets.
Q1 Revenue: ₹449 crRevenue vs TTM: ~31.6%EBITDA Margin: 27.5%FY28 Revenue Guidance: $400 millionCapex Program Commitment: 80% of $100m
📅 Short termPositive sentiment is expected as the company demonstrates strong margin recovery and successful execution of its semaglutide launch strategy.
📈 Long termStructural growth is supported by a tripling of sterile production capacity by FY28 and a shift toward high-margin biologics and drug-device combinations.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk on the $100m capex program
- Regulatory dependency (4 of 7 facilities are USFDA approved)
- Pricing pressure in the competitive CDMO landscape
Key Highlights
Revenue increased 37% YoY to ₹4,490 million (₹449 cr) for Q1FY27.
EBITDA margins expanded to 27.5%, representing a 600 bps improvement over the previous quarter.
Adjusted PAT grew 72% YoY to ₹637 million, excluding exceptional items and amortization.
Biologics RFP funnel grew 4x compared to FY25 levels, indicating strong future pipeline visibility.
Reaffirmed FY28 organic revenue guidance of $400 million with a 40% steady-state EBITDA margin.
👀 What to Watch
Monitor the successful commercialization of the second cartridge line in Q2FY27 and the conversion of the expanded biologics RFP funnel into firm Master Service Agreements (MSAs).
Management Change: Global Head of Injectables Resigns; Head of HR Designated as SMP
OneSource Specialty Pharma has announced the resignation of Ravi Kumar, Global Head of Injectables and Corporate Strategy, effective July 24, 2026. To fill the Senior Management Personnel (SMP) gap, the company has designated Preeti Kalra, Head of Human Resources, as an SMP. This leadership transition occurs while the company is loss-making (TTM PAT of -₹49 Cr) and managing a significant debt of ₹1,504 Cr. The departure of the Injectables head is particularly relevant as the company targets capacity expansion in this segment by CY 2026.
Confidence: HIGH
What changedThe Global Head of Injectables and Corporate Strategy has resigned, and the Head of Human Resources has been elevated to the Senior Management Personnel category.
Why it mattersLeadership stability in the Injectables division is crucial for OneSource, as this segment is a core growth driver and the company is currently navigating a period of net losses and restructuring.
TTM Revenue: ₹1422 CrTTM PAT: ₹-49 CrTotal Debt: ₹1504 CrNew SMP Experience: 25+ yearsInjectables Capacity: 40 million units
📅 Short termThe resignation of a key business head (Injectables/Strategy) may create short-term uncertainty regarding execution timelines for the current fiscal year.
📈 Long termThe company's ability to scale its CDMO business to 100 countries depends on stable leadership in its core modalities; frequent SMP changes could impact long-term strategic goals.
⚠ Risk flags
- Key personnel risk due to resignation of business head
- Ongoing net losses
- High working capital utilization (90%)
Key Highlights
Ravi Kumar resigned as Global Head – Injectables and Head of Corporate Strategy effective July 24, 2026.
Preeti Kalra, with over 25 years of experience in Biopharma and IT, designated as Senior Management Personnel.
Company maintains a TTM revenue of ₹1,422 Cr with a current debt-to-equity ratio of 0.25.
Injectables segment is critical with an installed capacity of 40 million units and expansion planned for CY 2026.
👀 What to Watch
Investors should monitor the announcement of a new head for the Injectables and Strategy division, as this role is vital for executing the integrated CDMO model and managing the 4 USFDA-approved facilities.
Onesource Specialty Pharma Q1 FY27 Results: Subsidiary Revenue at Rs 28.35 Cr
Onesource Specialty Pharma Limited reported its Q1 FY27 results for the period ended June 30, 2026. While the full consolidated P&L was not detailed in the auditor's extract, two key subsidiaries contributed Rs 28.35 cr in revenue with a net loss of Rs 1.21 cr. The company is currently in a transition phase following the restructuring of CDMO businesses from Strides and Steriscience. With a TTM revenue of Rs 1,422 cr and a recent history of volatility (Mar 2026 PAT of Rs 4.6 cr vs Dec 2025 loss of Rs 88.7 cr), the market will focus on the consolidated margin trajectory.
Confidence: MEDIUM
What changedThe company has released its first quarterly financial results for the 2026-27 fiscal year following its major CDMO restructuring.
Why it mattersAs a loss-making entity (TTM PAT of Rs -49 cr) with a high market cap of Rs 12,657 cr, consistent quarterly performance is critical to justify its valuation and the success of its integrated CDMO strategy.
Subsidiary Revenue (Q1): Rs 28.35 crSubsidiary Net Loss (Q1): Rs 1.21 crTTM Revenue: Rs 1422 crTotal Debt: Rs 1504 crMarket Cap: Rs 12657 cr
📅 Short termThe stock may see neutral to cautious movement as the market digests the full consolidated numbers and the performance of the newly integrated subsidiaries.
📈 Long termThe long-term outlook depends on the execution of the GLP-1 launch and the expansion into 100 countries, aiming for a 12% growth rate.
⚠ Risk flags
- Continued losses in several subsidiaries
- High debt-to-revenue ratio
- Regulatory risk with 50% of revenue tied to USFDA-approved facilities
Key Highlights
Two subsidiaries reported a combined revenue of Rs 28.35 cr (Rs 283.47 million) for the quarter ended June 30, 2026.
Net loss from these two subsidiaries stood at Rs 1.21 cr (Rs 12.14 million) for the same period.
Four other subsidiaries reported Nil revenue and a combined loss of Rs 0.18 cr (Rs 1.79 million).
The company maintains 7 manufacturing facilities, 4 of which are USFDA approved, supporting its CDMO model.
Consolidated debt remains a factor at Rs 1,504 cr against a TTM revenue of Rs 1,422 cr.
👀 What to Watch
Investors should monitor the full consolidated financial statement to see if the company has maintained the slim profitability achieved in Mar 2026 (Rs 4.6 cr) or reverted to losses.
OneSource Partners with Formycon AG for Strategic Biosimilar Manufacturing in Bangalore
OneSource Specialty Pharma has entered a strategic manufacturing partnership with Munich-based Formycon AG, a leading independent biosimilar developer. OneSource will provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing from its Bangalore facility, which is US FDA and EMA approved. Formycon currently has 3 biosimilars on the market and 4 candidates in its pipeline, including biosimilars for pembrolizumab and dupilumab. This partnership validates OneSource's biologics platform and provides a pathway to utilize its high-end manufacturing capacity for global markets.
Confidence: HIGH
What changedOneSource has transitioned from a general CDMO provider to a strategic manufacturing partner for a major European biosimilar developer.
Why it mattersThis partnership provides high-value biologics volume for OneSource's facilities, validating its technical capabilities in a high-margin segment and supporting its long-term growth strategy in regulated markets.
Biosimilars on market (Formycon): 3Pipeline candidates (Formycon): 4Approved manufacturing facilities: 5TTM Revenue: Rs 1422 CrMarket Cap: Rs 12803 Cr
📅 Short termThe announcement is likely to boost investor confidence as it provides external validation of the company's biologics infrastructure by a global player.
📈 Long termThis is structurally significant as it positions OneSource in the high-growth biosimilar CDMO space, potentially improving margins and asset turnover over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory compliance risks at the Bangalore facility
- Execution risks in complex biologics manufacturing
- Dependence on Formycon's clinical and market success
Key Highlights
OneSource to provide end-to-end Drug Substance and Drug Product manufacturing from its Bangalore biologics facility.
Formycon brings a portfolio of 3 marketed biosimilars and 4 pipeline candidates currently in development.
OneSource operates 5 manufacturing facilities approved by global regulatory authorities including the US FDA and EMA.
The company employs a dedicated team of over 1,600 professionals to support its global CDMO operations.
Formycon's pipeline includes high-value candidates like FYB206 (pembrolizumab) and FYB208 (dupilumab).
👀 What to Watch
Monitor the timeline for the commencement of commercial batches and the impact on capacity utilization at the Bangalore facility, which is key to reversing the current TTM net loss of Rs 49 Cr.
On eS o u r c e c l a r i f i e s n o m a t e r i a l i m p a c t f r o m D r . R e d d y ' s S e m a g l u t i d e s u p p l y d e l a y
On eS o u r c e S p e c i a l t y P h a r m a h a s c l a r i f i e d t h a t t h e d e l a y i n c o m m e r c i a l s u p p l i e s o f S e m a g l u t i d e a n n o u n c e d b y i t s p a r t n e r , D r . R e d d y ’ s L a b o r a t o r i e s ( D R L ) , w i l l n o t h a v e a m a t e r i a l f i n a n c i a l i m p a c t . T h e c o m p a n y s t a t e d t h a t i t s e x i s t i n g c a p a c i t i e s a r e f u l l y c o m m i t t e d t o o t h e r c u s t o m e r s , i n c l u d i n g t h o s e i n C a n a d a . A d d i t i o n a l l y , O n e S o u r c e i s p r o c e e d i n g w i t h s i g n i f i c a n t c a p a c i t y e x p a n s i o n s t a r t i n g t h i s q u a r t e r ( J u l y 2 0 2 6 ) t o m e e t f u t u r e d e m a n d . T h i s c l a r i f i c a t i o n i s c r i t i c a l g i v e n t h e c o m p a n y ' s p r e v i o u s g u i d a n c e o n G L P - 1 p r o d u c t s b e i n g a k e y g r o w t h d r i v e r .
Confidence: H I G H
What changedOn eS o u r c e i s r e s p o n d i n g t o a p u b l i c d e l a y a n n o u n c e m e n t b y i t s m a j o r p a r t n e r , D r . R e d d y ' s , r e g a r d i n g a s p e c i f i c h i g h - v a l u e p r o d u c t ( S e m a g l u t i d e ) .
Why it mattersIt a s s u r e s t h e m a r k e t t h a t t h e c o m p a n y ' s r e v e n u e s t r e a m i s d i v e r s i f i e d e n o u g h t o w i t h s t a n d a d e l a y f r o m a s i n g l e m a j o r c l i e n t i n t h e G L P - 1 s e g m e n t .
T T M R e v e n u e: ₹ 1 4 2 2 C rM a r k e t C a p: ₹ 1 2 4 1 5 C rI n s t a l l e d C a p a c i t y ( S t e r i l e ): 4 0 m i l l i o n u n i t sD e b t: ₹ 1 5 0 4 C r
📅 Short termT h e c l a r i f i c a t i o n i s l i k e l y t o p r e v e n t n e g a t i v e s p i l l o v e r s e n t i m e n t f r o m D r . R e d d y ' s a n n o u n c e m e n t o v e r t h e n e x t f e w t r a d i n g s e s s i o n s .
📈 Long termT h e c o m p a n y ' s a b i l i t y t o f i l l c a p a c i t y w i t h o t h e r c l i e n t s v a l i d a t e s i t s C D M O m o d e l , b u t l o n g - t e r m g r o w t h r e m a i n s t i e d t o t h e s u c c e s s f u l r a m p - u p o f i t s 2 0 2 6 e x p a n s i o n p l a n s .
⚠ Risk flags
- Cl i e n t c o n c e n t r a t i o n i n t h e G L P - 1 s e g m e n t
- Ex e c u t i o n r i s k o n n e w c a p a c i t y a d d i t i o n s
- Re g u l a t o r y d e p e n d e n c e o n U S F D A a p p r o v a l s
Key Highlights
Con f i r m e d n o m a t e r i a l f i n a n c i a l i m p a c t f r o m D R L ' s S e m a g l u t i d e s u p p l y d e l a y
Cur r e n t m a n u f a c t u r i n g c a p a c i t i e s a r e f u l l y c o m m i t t e d t o o t h e r g l o b a l c u s t o m e r s
Sig n i f i c a n t n e w c a p a c i t y a d d i t i o n s c o m m e n c i n g i n t h e c u r r e n t q u a r t e r ( Q 2 F Y 2 7 )
Mai n t a i n s a c u s t o m e r b a s e o f m o r e t h a n 2 5 p l a y e r s t o m i t i g a t e c o n c e n t r a t i o n r i s k s
👀 What to Watch
In v e s t o r s s h o u l d m o n i t o r t h e e x e c u t i o n t i m e l i n e o f t h e n e w c a p a c i t y e x p a n s i o n d u e i n C Y 2 0 2 6 a n d t h e r e s u m p t i o n o f D R L ' s c o m m e r c i a l s u p p l y t i m e l i n e .
1 Observation Issued Following US-FDA Inspection at Bengaluru Sterile Facility
Onesource Specialty Pharma completed a routine US-FDA cGMP inspection at its Sterile Product Division (SPD) facility in Bengaluru, conducted from June 22 to June 30, 2026. The inspection concluded with one observation, which the company intends to address within the stipulated timeframe. Maintaining regulatory compliance is critical as the company notes that non-compliance at its 4 US-FDA approved facilities could impact approximately 50% of its total revenue. This facility is central to the company's CDMO strategy involving sterile injectables and biologics.
Confidence: HIGH
What changedA routine US-FDA inspection at a key sterile manufacturing facility has concluded with a single procedural or technical observation.
Why it mattersFor a CDMO focused on sterile injectables and biologics, US-FDA compliance is the primary barrier to entry and a prerequisite for serving regulated markets; any escalation could jeopardize half of the company's revenue stream.
Observations issued: 1Inspection duration: 9 daysRevenue impact of non-compliance: 50%US-FDA approved facilities: 4
📅 Short termThe market is likely to remain neutral until the severity of the single observation is clarified through further company updates or the EIR.
📈 Long termMaintaining a clean regulatory track record is essential for the company's goal to expand into 100 countries and execute its GLP-1 launch strategy in FY25.
⚠ Risk flags
- Regulatory risk if the single observation is not addressed to the FDA's satisfaction
Key Highlights
Inspection concluded with 1 observation at the Bengaluru Sterile Product Division facility
Audit duration spanned 9 days from June 22, 2026, to June 30, 2026
Regulatory non-compliance at approved facilities poses a risk to 50% of total revenue
Company currently operates 4 US-FDA approved facilities out of a total of 7 manufacturing sites
👀 What to Watch
Investors should monitor for the issuance of the Establishment Inspection Report (EIR) to confirm if the observation is classified as NAI (No Action Indicated) or VAI (Voluntary Action Indicated).
OneSource Specialty Pharma Q4 Revenue Jumps 47% QoQ; Reaffirms $400M FY28 Revenue Target
OneSource Specialty Pharma reported a strong Q4 FY26 recovery with revenues reaching INR 4,282 million, a 47% sequential growth driven by the launch of generic Semaglutide in India. While full-year revenue saw a marginal 2% decline to INR 14,216 million due to earlier regulatory delays, the company has successfully secured approvals in Canada and tentative approval in the US. Management has deferred a proposed merger scheme with Steriscience and Brooks to address investor valuation concerns, focusing instead on organic growth. The company reaffirmed its ambitious FY28 guidance of $400 million in revenue with 40% EBITDA margins, supported by ongoing capacity expansions.
Key Highlights
Q4 FY26 revenue stood at INR 4,282 million ($48M), marking a 47% increase over the previous quarter.
Commenced commercial shipments of generic Semaglutide in India and received regulatory approvals for Canada and the US.
Reaffirmed long-term FY28 guidance of $400 million organic revenue and 40% EBITDA margins.
New production capacity for Drug Device Combinations (DDCs) to be operational by Q2 FY27.
Deferred the Steriscience and Brooks merger scheme for approximately two years to focus on governance and valuation alignment.
👀 What to Watch
Investors should focus on the successful commercialization of GLP-1 generics and the strong sequential growth as indicators of a turnaround. The management's decision to defer the merger to protect minority interests enhances governance credibility, making the stock a key watch for its FY28 targets.
OneSource Specialty Pharma Files Clean FY26 Audit Report and SMP Resignation Details
OneSource Specialty Pharma Limited has submitted formal documentation regarding the resignation of a Senior Management Personnel (SMP), following an initial disclosure on May 13, 2026. Accompanying this, the company released its Independent Auditor's Report for the fiscal year ended March 31, 2026, conducted by Deloitte Haskins & Sells. The auditors issued an unqualified 'true and fair' opinion on the standalone financial results for both the full year and the final quarter of FY26. This confirms the company's adherence to Indian Accounting Standards (Ind AS) and SEBI regulatory requirements.
Key Highlights
Deloitte Haskins & Sells issued an unqualified audit opinion for the fiscal year ended March 31, 2026.
The standalone financial results for FY26 were confirmed to be free from material misstatement.
The filing provides the formal resignation document for a Senior Management Personnel (SMP).
Financial reporting was found to be in full compliance with Ind AS and SEBI (LODR) Regulations.
The audit covered both the annual results and the specific quarter ended March 31, 2026.
👀 What to Watch
The clean audit report is a positive indicator of financial transparency; investors should monitor the company's upcoming appointments to fill the vacant SMP position.
OneSource Specialty Pharma Gets Karnataka Govt Nod for Unit II Expansion & Incentives
OneSource Specialty Pharma has secured in-principle approval from the Karnataka Government for its Unit II expansion project under the 2025-30 Industrial Policy. The approval, cleared by the 67th State High Level Clearance Committee, entitles the company to specific incentives and concessions for its facility in Bengaluru Rural. This expansion is a key part of the company's strategy to scale manufacturing capacity for global partners. The official government order was received on May 15, 2026, following the committee meeting held on April 13, 2026.
Key Highlights
In-principle approval received for Unit II expansion under Karnataka Industrial Policy 2025-30
Project cleared by the 67th State High Level Clearance Committee (SHLCC) on April 13, 2026
Expansion located at Obadenahalli, KIADB Industrial Area, Bengaluru Rural District
Company entitled to incentives and concessions to support manufacturing capacity growth
Flagship facility expansion aimed at enhancing services for global pharmaceutical partners
👀 What to Watch
Investors should view this as a positive development for long-term capacity building and margin improvement via government incentives. Monitor the company's upcoming capital expenditure plans and execution timelines for this expansion.
OneSource Q4FY26 Revenue up 47% QoQ to ₹4,282m; Reaffirms $400m FY28 Revenue Guidance
OneSource reported a strong sequential recovery in Q4FY26 with revenue growing 47% QoQ to ₹4,282 million and EBITDA expanding over 5x to ₹919 million. The quarterly performance was bolstered by the commercial launch of semaglutide in India and new launches in the US injectables and soft-gelatin segments. However, full-year FY26 results showed a decline, with revenue down 2% YoY to ₹14,216 million and Adjusted PAT falling 68% to ₹739 million due to delayed approvals and higher costs. The company reaffirmed its ambitious FY28 guidance of approximately $400 million in organic revenue with a 40% EBITDA margin.
Key Highlights
Q4FY26 Revenue grew 47% QoQ to ₹4,282 million; EBITDA margin expanded 1550 bps to 21%.
FY26 Adjusted PAT stood at ₹739 million, a 68% YoY decline from ₹2,314 million in FY25.
Company reaffirmed FY28 organic revenue target of ~$400 million with ~40% EBITDA margins.
Successfully launched semaglutide in India and secured first generic approvals in Canada and US.
Committed $80 million of a $100 million capex program to expand cartridge and biologics capacity.
👀 What to Watch
Investors should focus on the strong sequential turnaround and the company's strategic positioning in the high-growth GLP-1 (semaglutide) market. Monitor the execution of the FY28 guidance and the ramp-up of the new biologics and injectable capacities as key value drivers.
OneSource Q4FY26 Revenue Jumps 47% QoQ; Reaffirms FY28 Revenue Guidance of $400M
OneSource Specialty Pharma reported a strong sequential recovery in Q4FY26, with revenue growing 47% QoQ to ₹4,282 million and EBITDA expanding over 5x to ₹919 million. The performance was primarily driven by the commercial launch of generic Semaglutide in India and new product launches in the US. While FY26 was a transition year with a 35% YoY decline in EBITDA due to facility ramp-up costs, the company reaffirmed its ambitious FY28 guidance of $400 million in revenue with 40% margins. Management highlighted a robust pipeline with 50+ drug-device combination projects and growing momentum in the biologics segment.
Key Highlights
Q4FY26 revenue rose 47% QoQ to ₹4,282 million, supported by India Semaglutide launches.
EBITDA margin expanded by 1550 bps sequentially to 21% in Q4 from 6% in Q3.
Reaffirmed FY28 organic revenue guidance of ~$400 million with ~40% EBITDA margin.
Secured first generic Semaglutide approvals in Canada and US (tentative) for partners.
Committed $80 million of the planned $100 million capex for capacity expansion at flagship sites.
👀 What to Watch
Investors should focus on the company's successful entry into the high-growth GLP-1 market and the reaffirmed FY28 guidance as a sign of long-term value. Monitor the execution of the remaining $20 million capex and the ramp-up of the biologics pipeline for sustained growth.
OneSource Specialty Pharma Halts Merger with Steriscience; To Revisit Post-FY28
OneSource Specialty Pharma has announced that its Board of Directors decided not to pursue the proposed merger and acquisition of Steriscience facilities in Poland and Baroda in its current form. This decision marks a reversal from the in-principle approval received on February 26, 2026. The company intends to revisit the transaction only after the successful delivery of the respective companies' FY28 guidance. This strategic pause suggests a shift in focus toward operational performance over immediate inorganic expansion.
Key Highlights
Board decided to not pursue the composite scheme of arrangement involving Steriscience entities in its current form.
The acquisition would have included pharmaceutical facilities located in Poland and Baroda.
The transaction is deferred and will be revisited following the achievement of FY28 financial guidance.
The decision follows an earlier in-principle approval granted on February 26, 2026.
👀 What to Watch
Investors should monitor the company's organic growth and progress toward its FY28 targets, as the immediate boost from the Steriscience merger is now off the table. The stock may see some volatility as the market recalibrates the company's near-term growth trajectory.
OneSource Specialty Pharma Appoints B S R & Co LLP as New Auditors for 5-Year Term
OneSource Specialty Pharma has approved the appointment of B S R & Co LLP as its statutory auditors for a five-year term, starting from the 19th Annual General Meeting. This appointment replaces Deloitte Haskins & Sells, whose tenure is concluding. Alongside this change, the company reported its audited financial results for the fiscal year ended March 31, 2026, which received an unmodified opinion from the outgoing auditors. The transition to another major audit firm indicates a continued commitment to high-standard financial oversight.
Key Highlights
Appointment of B S R & Co LLP as statutory auditors for a 5-year term until the 24th AGM.
Outgoing auditors Deloitte Haskins & Sells issued an unmodified opinion for the FY26 financial results.
Board approved both standalone and consolidated audited financial results for the year ended March 31, 2026.
B S R & Co LLP is a major firm with over 4,000 personnel and 170 partners serving several listed Indian companies.
👀 What to Watch
The transition between two reputable 'Big Four' level firms is a routine governance practice; investors should review the full FY26 results for operational performance details.
OneSource Specialty Pharma Halts SteriScience Merger; To Revisit After FY28
OneSource Specialty Pharma has decided not to pursue the proposed acquisition of SteriScience facilities in Poland and Baroda in its current form. This decision comes despite receiving in-principle approval for the composite scheme of arrangement in February 2026. The Board has opted to revisit the transaction only after the involved companies successfully deliver on their FY28 financial guidance. This move effectively delays the inorganic growth and consolidation plans for the next two fiscal years.
Key Highlights
Board decided to halt the merger with Steriscience Specialties and Brooks Steriscience entities.
The acquisition of SteriScience facilities in Poland and Baroda is no longer being pursued in its current form.
Transaction revisit is deferred until after the delivery of respective companies' FY28 guidance.
The decision follows a previous in-principle approval update from February 26, 2026.
👀 What to Watch
Investors should focus on the company's standalone performance and organic growth prospects as the anticipated merger synergies are now delayed until at least FY28. Monitor management's commentary regarding the specific FY28 targets that must be met to restart the process.
OneSource Specialty Pharma Approves FY26 Results; Appoints B S R & Co LLP as Statutory Auditors
OneSource Specialty Pharma Limited has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The current statutory auditors, Deloitte Haskins & Sells, have issued an unmodified opinion, confirming the reliability of the financial statements. In a significant governance move, the board has recommended the appointment of B S R & Co LLP as the new statutory auditors for a five-year term, effective from the conclusion of the 19th AGM. This transition occurs as the tenure of the existing auditors reaches its conclusion.
Key Highlights
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Statutory auditors issued a declaration of unmodified opinion for the financial year 2025-26.
Proposed appointment of B S R & Co LLP as statutory auditors for a consecutive term of five years.
B S R & Co LLP will replace Deloitte Haskins & Sells, whose term ends at the ensuing Annual General Meeting.
The board meeting was conducted on May 13, 2026, between 11:30 hrs and 12:55 hrs IST.
👀 What to Watch
Investors should review the detailed financial performance metrics once the full report is available to gauge operational growth. The transition to B S R & Co LLP is a routine auditor rotation and maintains the company's engagement with top-tier audit firms.
OneSource Supports Second Generic Semaglutide Approval in Canada for Global Partners
OneSource Specialty Pharma's partner, Orbicular, has received Health Canada approval for a generic version of Ozempic (semaglutide injection). This marks the second generic semaglutide approval in Canada, which is the world's second-largest market for this drug. OneSource serves as the end-to-end manufacturing partner and will supply the product from its US FDA-approved flagship facility in Bengaluru. This milestone follows a recent tentative US approval and successful product launches in India earlier in March 2026.
Key Highlights
Health Canada approval secured for generic semaglutide injection in the world's second-largest market.
OneSource to provide end-to-end manufacturing from its US FDA-approved Bengaluru facility.
Follows a recent tentative US approval, strengthening the company's global CDMO positioning.
Company already supports multiple partners in India following product launches in March 2026.
Leverages a workforce of 1,600+ professionals and 5 state-of-the-art manufacturing facilities.
👀 What to Watch
Investors should monitor the revenue ramp-up from the Canadian market as OneSource transitions to commercial supply. The company's success in the high-growth GLP-1 (semaglutide) space validates its technical expertise in complex drug-device combinations.
OneSource Partner Dr. Reddy's Receives Health Canada Approval for Generic Semaglutide Injection
OneSource Specialty Pharma's partner, Dr. Reddy's Laboratories, has received a Notice of Compliance from Health Canada for a generic version of Ozempic (Semaglutide Injection). OneSource serves as the exclusive CDMO partner for this program, providing scale-up and commercial manufacturing from its US-FDA approved flagship facility in Bengaluru. This approval validates OneSource's technical capabilities in the high-growth peptide and GLP-1 market segment. The company currently operates five state-of-the-art manufacturing facilities and employs a team of over 1,600 professionals.
Key Highlights
Partner Dr. Reddy's receives Health Canada approval for Generic Semaglutide (Ozempic generic).
OneSource to handle commercial manufacturing at its US-FDA approved flagship Bengaluru facility.
The company operates 5 global regulatory-approved manufacturing facilities with 1,600+ professionals.
Validation of OneSource's CDMO capabilities in complex peptide development and sterile injectables.
👀 What to Watch
Investors should view this as a major milestone that positions OneSource as a key player in the global GLP-1 supply chain. Monitor the stock for potential revenue growth as commercial production scales up for the Canadian market.
